{"contentid": 488762, "importid": NaN, "name": "ProBioGen and Minapharm incorporate MiGenTra", "introduction": "ProBioGen and Egyptian firm Minapharm Pharmaceuticals, which owns 96.79% of Germany-based ProBioGen, have announced the incorporation of ProBioGen's subsidiary MiGenTra GmbH with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant.", "content": "<p>ProBioGen and Egyptian firm Minapharm Pharmaceuticals, which owns 96.79% of Germany-based ProBioGen, have announced the incorporation of ProBioGen's subsidiary MiGenTra GmbH with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant.</p>\n<p>The formation of MiGenTra accelerates ProBioGen's 2030 growth roadmap and showcases that further growth is not limited to the ongoing capacity increase but reveals one of several significant steps in the diversification of ProBioGen's business.</p>\n<p>MiGenTra will enhance the accessibility to critical healthcare transforming medicines at affordable prices for Egypt, the Middle East and Africa (MEA) while simultaneously strengthening regional and local manufacturing capacities. The company will respond to urgent unmet medical needs, supporting efforts by the World Health Organization (WHO) and the International Finance Corporation (IFC).</p>\n<p>MiGenTra combines the scientific and manufacturing expertise from both contributing companies, ProBioGen and Minapharm Pharmaceuticals. It is established for product development and commercialization in the field of Biosimilars, Cell and Gene Therapies (CGT) and vaccines, capitalizing on the strong development capabilities of ProBioGen and the excellent market position of Minapharm in the region.</p>\n<h2><strong>Already producing Sputnik V</strong></h2>\n<p>In April this year, Minapharm and ProBioGen agreed to establish a manufacturing base for Russia&rsquo;s homegrown coronavirus vaccine, Sputnik V. Technology transfer commenced immediately, with up to 40 million doses being produced annually at Minapharm&rsquo;s biotech facility in Cairo, for global distribution.</p>\n<p>\"MiGenTra marks a starting point of practice to consolidate an international platform of intelligent biopharmaceutical technologies with a longstanding regional process development and manufacturing expertise in the Middle East and Africa. Minapharm has demonstrated the feasibility of aligning economic interests and equality in access to affordable complex genetically engineered medicines. The COVID-19 pandemic has once again exposed global inequalities the world has ignored for too long. MiGenTra pledges to ensure equitable access to essential medicines, thereby contributing to the Global Health Initiative,\" said Minaphar, chairman and chief executive Wafik Bardissi.</p>", "date": "2021-05-27 13:44:00", "meta_title": "ProBioGen and Minapharm incorporate MiGenTra", "meta_keywords": "ProBioGen, Minapharm, MiGenTra, Incorporation, Manufacturing, Cell and gene, Vaccines, Sputnik V", "meta_description": "ProBioGen and Minapharm incorporate MiGenTra", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-27 13:43:16", "updated": "2021-05-27 14:14:59", "access": NaN, "url": "https://www.thepharmaletter.com/article/probiogen-and-minapharm-incorporate-migentra", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "probiogen-big.png", "image2id": "probiogen-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biosimilars, Pharmaceutical", "therapy area_tag": "Cell and Gene Therapy, Infectious diseases, Vaccines", "topic_tag": "Companies, mergers and acquisitions, Coronavirus, Management, Production", "geography_tag": "Egypt, Germany", "company_tag": "MiGenTra, Minapharm, ProBioGen", "drug_tag": "Sputnik V", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-27 13:44:00"}